新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 诺华 » 罚罚罚!诺华-罗氏反竞争勾当面临意大利卫生部€12亿索赔

罚罚罚!诺华-罗氏反竞争勾当面临意大利卫生部€12亿索赔

来源:生物谷 2014-12-04 09:49

2014年12月4日讯 /生物谷BIOON/ --重大挫折!意大利地方法院近日维持了最初由意大利反垄断机构关于诺华和罗氏相互勾结反竞争行为的判决。

瑞士2大制药巨头诺华和罗氏表示,迄今为止只被口头告知意大利拉齐奥地方法院的裁决,双方将会提起上诉。目前,诺华和罗氏也正面临着来自意大利卫生部超过10亿欧元的赔偿金。

今年3月,因涉嫌串通阻止将安维汀(Avastin)用于一种眼科疾病的治疗,诺华和罗氏遭意大利反垄断机构罚款1.825亿欧(约合2.51亿美元)。该反垄断机构在官网发文称,诺华和罗氏非法阻断Avastin的分销,以利于其更昂贵的眼科药物Lucentis的销售。之后在今年5月,意大利卫生部表示将对诺华和罗氏索赔12亿欧元。

诺华表示,坚决反对反竞争行为的任何指控,并称这些指控毫无根据,将采取一切必要措施提起上诉。罗氏也表示,坚决不同意意大利地方法院的判决,该公司重申,针对反竞争行为的任何指控毫无根据。罗氏发言人表示,自今年5月底收到意大利卫生部打算索赔12亿欧赔偿金的信件之后,对方一直未联系公司。

根据今年3月的指控,罗氏和诺华通过“人为区化”这2种药品,仅2012年就让意大利医疗系统多花了超过4500万欧,而可能的未来成本,将每年超过6000万欧。另外,罗氏没有寻求意大利监管部门批准将Avastin用于湿性年龄相关性黄斑变性(wet-AMD),却在美国努力寻求扩大Avastin适应症用于黄斑变性的治疗。在2010年的一项研究表明,用于治疗wet-AMD时,Avastin疗效媲美Lucentis。(生物谷Bioon.com)

英文原文:Novartis and Roche suffer setback in Italian collusion case

(Reuters) - Swiss drugmaker Novartis said a regional court in Italy had upheld a decision by Italian antitrust authorities which found Novartis and Roche colluded in anti-competitive practices.

Novartis and Roche, which deny wrongdoing, said on Tuesday they had so far only been verbally informed of the regional administrative tribunal of Lazio's decision and would appeal the verdict.

The rejection of their appeal is a setback for the two Swiss drugmakers which also face demands for more than a billion euros in damages from the Italian health ministry over the alleged collusion.

In March, the Italian Competition Authority fined Novartis and Roche 182.5 million euros ($226 million) for colluding to try to impose Novartis' Lucentis as a treatment for a serious eye disease instead of Roche's cheaper Avastin.

In May, the Italian health ministry said it would seek 1.2 billion euros in damages from the companies.

"Novartis firmly rejects the accusations of anti-competitive practices and any allegations of anti-competitive behavior are unfounded and without merit. We will take all necessary steps to appeal this decision," the company said on Tuesday.

Roche also said it strongly disagreed with the court's decision. "We reiterate that the charges are unfounded and will appeal the verdict. There was no collusion with Novartis," it said.

Roche spokeswoman Claudia Schmitt told Reuters the company had not been contacted again by Italy's health ministry after receiving a letter at the end of May announcing the ministry's intention to seek damages.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库